中国综合性科技类核心期刊(北大核心)
中国科学引文数据库来源期刊(CSCD)
美国《化学文摘》(CA)收录
美国《数学评论》(MR)收录
俄罗斯《文摘杂志》收录
Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!
| Name | |
|---|---|
| Phone | |
| Title | |
| |
| Citation: | QI Long, ZUO Di, WANG Hui, LI Xiao-tao. Expressions of REGγ, p53, NOTCH1 and BRAF gene in thyroid cancer and their clinical relevance[J]. Journal of East China Normal University (Natural Sciences), 2012, (6): 89-95.
|
| [1] |
［1］ OKAMURA T,TANIGUCHI S,OHKURA T,et al.Abnormally high expression of proteasome activator-gamma in thyroid neoplasm［J］. J Clin Endocrinol Metab， 2003， 88(3): 1374-1383.［2］ RODERICK M，HELEN G，PAOLO G, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and 〖STBX〗p53〖STBZ〗 mutations［J］. CANCER， 2005， 103(11): 2261-2268.［3］ KIMURA E T, NIKIFOROVA M N, ZHU Z, et al. High prevalence of 〖WTBX〗BRAF〖WTBZ〗 mutations in thyroid cancer genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma［J］. CANCER RESEARCH, 2003, 63: 1454-1457.［4］ PRATHIBHA R, WEAVER K L, CAPOBIANCO A J. Notch signalling in solid tumours: a little bit of everything but not all the time［J］. Nature， 2011（11）: 338-351.［5］ NIKIFOROVA M N, KIMURA E T, GANDHI M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas［J］. J Clin Endocrinol Metab, 2003, 88(11): 5399-5540.［6］ 沈铭昌.免疫组化在病理学中的应用进展与评价［J］.实用肿瘤杂志, 2002, 17（5）： 293-294.［7］ MAO I, LIU J, LI X, et al. REGgamma, a proteasome activator and beyond［J］. Cell Mol Life Sci， 2008， 65(24): 3971-80.［8］ NIKAIDO T, SHIMADA K, SHIBATA M, et al. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus［J］. Clin Exp Immunol, 1990, 79(2): 209-214.［9］ ROESSLER M, ROLLINGER W, MANTOVANI-ENDL L,et,al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis［J］. Mol Cell Proteomics, 2006, 5(11): 2092-2101.［10］ OKAMURA T, TANIGUCHI S, OHKURA T,et al. Abnormally high expression of proteasome activator-gamma in thyroid neoplasm［J］. J Clin Endocrinol Metab, 2003, 88(3): 1374-1383.［11］ SALVATORE G, NAPPI TC, SALERNO P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma［J］. Cancer Res, 2007, 67(21): 10148-10158.［12］ DAVIDOFFf A M, HEMDON J E, GLOVER N S, et al. Relation between 〖STBX〗p53〖STBZ〗 overexpression and established prognostic factors in breast cancer［J］. Surgery, 1991, 110(2): 259-264.［13］ ZHANG Z, ZHANG R.Proteasome activator PA28 gamma regulates 〖STBX〗p53〖STBZ〗 by enhancing its MDM2-mediated degradation［J］. EMBO J, 2008, 27(6): 852-64.［14］ PEYSSONNAUX C,EYCHENE A. The RAF/MEK/ERKpathway: new concepts of activation［J］. Biol Cell, 2001, 93: 53-62.［15］ DUESBERY N S,WEBB C P,VANDE W G F.MEK wars,a new front in the battle against cancer［J］. Nat Med, 1999(5): 736-742.［16］ PARR C,WATKINS G, JIANG W G. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumer clinicopathological parameters in human breast cancer［J］. Int J Med, 2004, 14(5): 779-786.［17］ QI R, AN H, YU Y, et al. 〖STBX〗NOTCH1〖STBZ〗 signaling inhibits growth of human hepatocellular crcinoma through induction of cell cycle arrest and apoptosis［J］. Cancer Res, 2003, 63: 8323-8329.
|
DownLoad: